Rare Neurological Disease Treatment Market is expected to reach US$13,830.96Mn in 2027

Published Date: 30 Mar 2020

Report : Rare Neurological Disease Treatment Market to 2027 - Global Analysis and Forecasts by Indication (Narcolepsy, Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Multiple Sclerosis, Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy, Other Indication); Drug Type (Organic Compounds, Biologics); Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies); Mode of Administration (Oral, Injectables) and Geography

Alzheimer’s diseaseSegment byindicationisexpectedtogrowat A Fast Pace overthe Forecast Period

 

According to The Insight Partners market research study of ‘Rare Neurological Disease TreatmentMarketto 2027 – Global Analysis and Forecasts by Indication, Drug Type, Distribution Channel, and Mode of Administration.’ The global rare neurological disease treatmentmarket is expected to reach US$ 13,830.96 Mn in 2027 from US$ 7,300.12Mn in 2019. The market is estimated to grow with a CAGR of 8.5% from 2020-2027. The report provides trends prevailing in the global rare neurological disease treatment marketand the factors driving market along with those that act as hindrances.

 

The global rare neurological disease treatmentmarket, based on the indication, is segmented into narcolepsy, amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis, and other indications.In 2019, the Alzheimer’s disease segment accounted for the largest market share in the global rare neurological disease treatment market. The growth of Alzheimer’s disease is attributed to an increasing prevalence of the disease across the world. According to the factsheet “2019 Alzheimer’s Disease Facts and Figures” approximately 5.8 million people in the US suffer from Alzheimer’s disease. The symptoms are widely seen in the geriatric group. Thus, the rising geriatric population across the globe is likely to influence market growth during the forecast period.

 

The rare neurological disease treatment marketfor is expected to grow, owing to factors such asgrowth rising prevalence of rare neurological diseases, and favorable pipeline drugs and robust research activities for the treatment of rare neurological diseases. Moreover, increasing awareness of rare neurological diseases coupled with developing healthcare infrastructureislikely to have a positive impact on the growth of the market in coming years.

 

Leading companies operating in the Rare Neurological Disease Treatment marketare Allergan plc, Bayer AG, GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd and Takeda Pharmaceutical Company Limited, among others.

 

The report segments global Rare Neurological Disease Treatment market as follows:

Global Rare Neurological Disease Treatment Market– By Indication

  • Narcolepsy
  • Amyotrophic Lateral Sclerosis
  • Alzheimer’s Disease
  • Multiple Sclerosis
  • Spinal Muscular Atrophy (SMA)
  • Duchenne Muscular Dystrophy
  • Other Indications

Global Rare Neurological Disease Treatment Market– By Drug Type

  • Organic Compounds
  • Biologics

GlobalRare Neurological Disease Treatment Market– By Distribution Channel

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Global Rare Neurological Disease Treatment Market – By Mode of Administration

  • Oral
  • Injectable


Global Rare Neurological Disease TreatmentMarket– By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • U.K
    • Spain
    • Italy
  • Asia Pacific (APAC)
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • U.A.E
    • South Africa
  • South & Central America (SCAM)
    • Brazil
    • Argentina

 

Contact Us

Contact Person: Sameer Joshi 

Phone: +1-646-491-9876

Email Id: sales@theinsightpartners.com

 

 

Download PDF Brochure